Relevant bibliographies by topics / Voriconazol

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Voriconazol'

Author: Grafiati
Published: 4 June 2021
Last updated: 25 April 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Voriconazol.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Voriconazol"

1

Figueras, Concepción, Miguel Lanaspa, and Pere Soler-Palacín. "Monitorización terapéutica de voriconazol." Anales de Pediatría Continuada 8, no. 2 (2010): 88–91. http://dx.doi.org/10.1016/s1696-2818(10)70016-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Serra Soler, G., O. Delgado Sánchez, E. Esteban Marcos, I. Martínez-López, and M. Femenías Sureda. "Fototoxicidad asociada al voriconazol." Farmacia Hospitalaria 30, no. 6 (2006): 386–87. http://dx.doi.org/10.1016/s1130-6343(06)74012-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

red. "EU-Zulassungserweiterung für Voriconazol." Im Focus Onkologie 18, no. 1-2 (2015): 83. http://dx.doi.org/10.1007/s15015-015-1619-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ruiz-Boy, Sonia, Carla Bastida, Merce Brunet, and Dolors Soy. "Evaluación de las concentraciones plasmáticas de voriconazol en práctica clínica." Ars Pharmaceutica (Internet) 62, no. 3 (2021): 305–14. http://dx.doi.org/10.30827/ars.v62i3.20756.

Full text
Abstract:
Introducción: Voriconazol presenta una alta variabilidad interindividual en sus concentraciones plasmáticas (Cp). Los objetivos son: (i) describir sus Cp en una cohorte adulta, (ii) estudiar sus potenciales causas de variabilidad y (iii) relacionarlas con las recomendaciones de monitorización farmacocinética actuales.
 Método: Estudio observacional retrospectivo, incluyendo pacientes con ≥1 determinación de Cp mínima (Cmin) de voriconazol durante 2017.
 Resultados: Se analizaron 165 Cmin correspondientes a 51 pacientes. La mediana de Cmin fue de 2,4µg/mL (IQR:1,4-3,6), siendo <1µg
APA, Harvard, Vancouver, ISO, and other styles
5

Ruhnke, M. "Voriconazol - Perspektiven und klinische Aspekte." Mycoses 45, S3 (2002): 42–47. http://dx.doi.org/10.1111/j.1439-0507.2002.tb04769.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Retamal, José, Gonzalo Ordenes-Cavieres, and Arturo Grau-Diez. "Natamycin versus voriconazole for fungal keratitis." Medwave 18, no. 08 (2018): e7388-e7388. http://dx.doi.org/10.5867/medwave.2018.08.7387.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

San Juan, Javier L., Carlos M. Fernández, Michel Almaguer, et al. "In vitro susceptibility of Cuban Aspergillus spp. strains of clinical and environmental origin." Biomédica 37, no. 4 (2017): 451. http://dx.doi.org/10.7705/biomedica.v37i4.3447.

Full text
Abstract:
Introducción. En Cuba se desconoce el comportamiento de la sensibilidad de Aspergillus spp. a los antifúngicos recomendados para el tratamiento de la aspergilosis: la anfotericina B, el itraconazol, el voriconazol y las equinocandinas. La influencia del ambiente puede condicionar la aparición de resistencia en estos microorganismos.Objetivo. Evaluar la sensibilidad in vitro de cepas de Aspergillus spp. a la anfotericina B, el itraconazol y el voriconazol, y la relación de los patrones de sensibilidad con su origen.Materiales y métodos. Se determinaron las concentraciones inhibitorias mínimas d
APA, Harvard, Vancouver, ISO, and other styles
8

Pincelli, Thaís Prota Hussein, Hebert Roberto Clivati Brandt, Adriana Lopes Motta, Felipe Vieira Rodrigues Maciel, and Paulo Ricardo Criado. "Fusariose em paciente imunocomprometido: sucesso terapêutico com voriconazol." Anais Brasileiros de Dermatologia 83, no. 4 (2008): 331–34. http://dx.doi.org/10.1590/s0365-05962008000400007.

Full text
Abstract:
A infecção por Fusarium solani é afecção fúngica potencialmente grave em pacientes imunocomprometidos, sobretudo naqueles portadores de neoplasias hematológicas. A mortalidade é alta,sendo limitadas as opções terapêuticas devido às condições da imunidade do doente e à relativa resistência do fungo aos antifúngicos utilizados de rotina. O voriconazol tem-se mostrado boa alternativa terapêutica em pacientes neutropênicos que apresentam fusariose refratária ou pouco responsiva à anfotericina B. Neste artigo relata-se caso de fusariose em doente imunocomprometido tratado com sucesso com voriconazo
APA, Harvard, Vancouver, ISO, and other styles
9

Flox Benítez, G., P. Rondón Fernández, M. Quero Escalada, and Á. Fernández Ballesteros. "Alucinosis como efecto secundario de voriconazol." Revista Clínica Española 205, no. 12 (2005): 632–33. http://dx.doi.org/10.1016/s0014-2565(05)72663-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Kammerer, Susanne. "Voriconazol erhöht das Risiko für Plattenepithelkarzinome." hautnah dermatologie 31, no. 3 (2015): 49. http://dx.doi.org/10.1007/s15012-015-1841-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Voriconazol"

1

Araújo, Bibiana Verlindo de. "Modelagem farmacocinética-farmacodinâmica do antifúngico voriconazol." reponame:Biblioteca Digital de Teses e Dissertações da UFRGS, 2008. http://hdl.handle.net/10183/12602.

Full text
Abstract:
Objetivos: O objetivo deste trabalho foi o desenvolvimento de um modelo farmacocinético/farmacodinâmico (PK/PD) para descrever o efeito antifúngico voriconazol (VRC) contra espécies de Candida. Método: Para alcançar este objetivo as seguintes etapas foram realizadas: i) foi adaptado e padronizado modelo de candidíase disseminada em ratos Wistar imunocompetentes e imunocomprometidos com Candida sp.; ii) foram validados métodos analíticos de LC-MS/MS e LC-UV para o doseamento do VRC em amostras de plasma e microdialisado de tecido; iii) foram estabelecidas as condições para microdiálise do VRC e
APA, Harvard, Vancouver, ISO, and other styles
2

Adams, Andréa Inês Horn. "Análise químico-farmacêutica e estudo de estabilidade do voriconazol." reponame:Biblioteca Digital de Teses e Dissertações da UFRGS, 2007. http://hdl.handle.net/10183/11060.

Full text
Abstract:
Este trabalho apresenta estudo sobre o voriconazol, antifúngico de amplo espectro liberado para tratamento de infecções fúngicas invasivas no ano de 2002, focado no controle de qualidade e estudo de estabilidade. Foram realizados testes, ainda não citados na literatura, que visaram à caracterização do fármaco tais como: espectrofotometria na região do infravermelho, espectroscopia de ressonância magnética nuclear de hidrogênio e de carbono. Os seguintes métodos de análise quantitativa do fármaco em comprimidos foram desenvolvidos e validados: espectrofotometria na região do UV, cromatografia a
APA, Harvard, Vancouver, ISO, and other styles
3

Rocha, Kamilla Amaral David. "Desenvolvimento de formulações contendo voriconazol encapsulado em nanopartículas lipídicas e promotores químicos de absorção para aplicação tópica na unha." Universidade Federal de Goiás, 2015. http://repositorio.bc.ufg.br/tede/handle/tede/8190.

Full text
Abstract:
Submitted by Liliane Ferreira (ljuvencia30@gmail.com) on 2018-02-28T14:49:21Z No. of bitstreams: 2 Dissertação - Kamilla Amaral David Rocha - 2015.pdf: 3193387 bytes, checksum: 6cc146ed197535b6a21627e8ffa4891c (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5)<br>Approved for entry into archive by Luciana Ferreira (lucgeral@gmail.com) on 2018-02-28T16:16:32Z (GMT) No. of bitstreams: 2 Dissertação - Kamilla Amaral David Rocha - 2015.pdf: 3193387 bytes, checksum: 6cc146ed197535b6a21627e8ffa4891c (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5
APA, Harvard, Vancouver, ISO, and other styles
4

Bravo, Villegas Esteban. "Validación del procedimiento de análisis de test de esterilidad y test de determinación endotoxinas bacterianas, para viales con polvo para reconstitución de Pemetrexed 500 mg, Voriconazol 200 mg y ampollas inyectables de Ondansetron 2 mg/mL." Tesis, Universidad de Chile, 2016. http://repositorio.uchile.cl/handle/2250/140222.

Full text
Abstract:
Unidad de práctica para optar al título de Químico Farmacéutico<br>Autor no autoriza el acceso a texto completo de su documento<br>En el presente trabajo se realizaron análisis para la Validación de las metodologías analíticas: Análisis de determinación Endotoxinas Bacterianas y Análisis de test esterilidad, utilizadas en el laboratorio de Microbiología, Departamento de Operaciones Analíticas del laboratorio farmacéutico Synthon Chile. Estos análisis fueron dirigidos a tres productos farmacéuticos estériles. Para el Análisis de Determinación Endotoxinas Bacterianas se realizó una evaluación d
APA, Harvard, Vancouver, ISO, and other styles
5

Benedetti, Naiara Ieza Gallo de Magalhães. "Estudo da encapsulação do voriconazol em lipossomas: obtenção, caracterização e estudo de estabilidade." Universidade Federal de Goiás, 2017. http://repositorio.bc.ufg.br/tede/handle/tede/9055.

Full text
Abstract:
Submitted by Liliane Ferreira (ljuvencia30@gmail.com) on 2018-11-12T13:58:06Z No. of bitstreams: 2 Dissertação - Naiara Ieza Gallo de Magalhães Benedetti - 2017.pdf: 10506850 bytes, checksum: 857e24de3790c59fd1f7dbf3e08ee0f3 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5)<br>Rejected by Luciana Ferreira (lucgeral@gmail.com), reason: A data da defesa, na citação, é 2017 e não 2018 on 2018-11-12T14:13:08Z (GMT)<br>Submitted by Liliane Ferreira (ljuvencia30@gmail.com) on 2018-11-12T14:20:07Z No. of bitstreams: 2 license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998
APA, Harvard, Vancouver, ISO, and other styles
6

Gürel, Gülhan [Verfasser], and Efdal [Akademischer Betreuer] Yörük. "Untersuchung der Biokompatibilität von Voriconazol (Vfend) auf humane korneale Epithelzellen / Gülhan Gürel ; Betreuer: Efdal Yörük." Tübingen : Universitätsbibliothek Tübingen, 2015. http://d-nb.info/1197693734/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ribeiro, Aline Dias. "Ocorrência de infecção nosocomial por Candida spp. no Hospital Universitário Cassiano Antonio de Moraes (HUCAM) e avaliação da anfotericina b e voriconazol na inibição de formação de biofilme pelas espécies isoladas." Universidade Federal do Espírito Santo, 2013. http://repositorio.ufes.br/handle/10/5887.

Full text
Abstract:
Made available in DSpace on 2016-12-23T13:55:58Z (GMT). No. of bitstreams: 1 Aline Dias Ribeiro.pdf: 1981766 bytes, checksum: cf9b688ead72c08ab9f20a3a8c84afcc (MD5) Previous issue date: 2013-08-09<br>INTRODUÇÃO: Infecções de corrente sanguínea por fungos têm se destacado principalmente pelo crescente número de casos de candidemia (infecções por Candida spp neste sítio). Atualmente, este fungo figura como um dos sete patógenos mais comuns em infecções nosocomiais, apresentando taxas de mortalidade bruta entre 40 e 70% e atribuída, de 50%. Formação de biofilme é frequentemente associada a pers
APA, Harvard, Vancouver, ISO, and other styles
8

Tilsen, Jörn Florian [Verfasser], Dirk [Gutachter] Schlüter, and Mathias [Gutachter] Pletz. "Therapeutisches Drug Monitoring von Voriconazol auf der Intensivstation / Jörn Florian Tilsen ; Gutachter: Dirk Schlüter, Mathias Pletz." Magdeburg : Universitätsbibliothek Otto-von-Guericke-Universität, 2019. http://d-nb.info/1220035122/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Tilsen, Jörn Florian Verfasser], Dirk [Gutachter] [Schlüter, and Mathias [Gutachter] Pletz. "Therapeutisches Drug Monitoring von Voriconazol auf der Intensivstation / Jörn Florian Tilsen ; Gutachter: Dirk Schlüter, Mathias Pletz." Magdeburg : Universitätsbibliothek Otto-von-Guericke-Universität, 2019. http://nbn-resolving.de/urn:nbn:de:gbv:ma9:1-1981185920-139323.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Mario, Débora Alves Nunes. "ATIVIDADE DAS EQUINOCANDINAS, ANFOTERICINA B E VORICONAZOL FRENTE A ISOLADOS DE Candida glabrata SENSÍVEIS E RESISTENTES AO FLUCONAZOL." Universidade Federal de Santa Maria, 2012. http://repositorio.ufsm.br/handle/1/5906.

Full text
Abstract:
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior<br>Widespread and prolonged usage of azoles in recent years has led to the rapid development of drug resistance in Candida species. In Candida albicans, resistance to fluconazole causes cross-resistance to other antifungals and an increase in virulence, making treatment still more difficult because of the limited therapeutical options. Nonetheless, similar phenomenon has been observed for Candida glabrata, specie that has emerged as a pathogen of clinical importance. Fluconazole resistance has been clinically described in Candida glab
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Voriconazol"

1

Blokdijk, G. J. Voriconazole; A Clear and Concise Reference. CreateSpace Independent Publishing Platform, 2018.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Angelini, Andrea. Voriconazole: Pharmacokinetics, Role in Therapeutic Drug Monitoring and Clinical Outcomes. Nova Science Publishers, Incorporated, 2015.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ashbee, H. Ruth. Antifungal therapeutic drug monitoring. Edited by Christopher C. Kibbler, Richard Barton, Neil A. R. Gow, Susan Howell, Donna M. MacCallum, and Rohini J. Manuel. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198755388.003.0048.

Full text
Abstract:
Therapeutic drug monitoring (TDM), the process of measuring drug concentrations in patients at specified time intervals, aims to ensure that the drug concentrations remain within the efficacious and non-toxic range for that drug. This chapter reviews the rationale for the use of TDM in antifungal therapy, specifically for flucytosine and azoles, including fluconazole, itraconazole, voriconazole, and posaconazole. For each antifungal drug, the bioavailability and excretion of the drug are detailed, as well as specific factors affecting antifungal drug concentrations in patients. The chapter dis
APA, Harvard, Vancouver, ISO, and other styles
4

Bicanic, Tihana, and Thomas S. Harrison. Fungal central nervous system infections. Edited by Christopher C. Kibbler, Richard Barton, Neil A. R. Gow, Susan Howell, Donna M. MacCallum, and Rohini J. Manuel. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198755388.003.0022.

Full text
Abstract:
Infections of the central nervous system (CNS) are amongst the most severe of all fungal infections. Cryptococcus neoformans is the commonest cause of adult meningitis in many countries with high HIV prevalence. C gattii is usually seen in the tropics in apparently immunocompetent patients. Meningitis is also caused by Candida in premature babies, and by the dimorphic fungi in endemic areas. CNS infections with Aspergillus, the mucormycetes, and less common moulds usually present as intracranial mass lesions in immunocompromised hosts. Early suspicion, prompt imaging, and appropriate samples f
APA, Harvard, Vancouver, ISO, and other styles
5

Jacobs, Samantha E., Catherine B. Small, and Thomas J. Walsh. Fungal diseases of the respiratory tract. Edited by Christopher C. Kibbler, Richard Barton, Neil A. R. Gow, Susan Howell, Donna M. MacCallum, and Rohini J. Manuel. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198755388.003.0030.

Full text
Abstract:
Fungal respiratory infections are important causes of morbidity and mortality in immunocompromised patients. Invasive aspergillosis remains the most common invasive fungal infection whereas other filamentous fungi, such as Fusarium spp., Mucorales, and Scedosporium spp., are increasing in frequency, particularly in neutropenic hosts. Endemic mycoses, including those due to Histoplasma capsulatum, Coccidioides spp., and Talaromyces marneffei, are increasingly prevalent in patients with cell-mediated immunodeficiencies in respective geographic regions. Culture remains the gold standard of diagno
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Voriconazol"

1

Mehlhorn, Heinz. "Voriconazole." In Encyclopedia of Parasitology. Springer Berlin Heidelberg, 2016. http://dx.doi.org/10.1007/978-3-662-43978-4_4924.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Mehlhorn, Heinz. "Voriconazole." In Encyclopedia of Parasitology. Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-642-27769-6_4924-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Molinelli, Alejandro R., and Charles H. Rose. "Quantification of the Triazole Antifungal Compounds Voriconazole and Posaconazole in Human Serum or Plasma Using Liquid Chromatography Electrospray Tandem Mass Spectrometry (HPLC-ESI-MS/MS)." In Methods in Molecular Biology. Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-3252-8_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

"Voriconazol." In Checkliste Arzneimittel A–Z, edited by Detlev Schneider and Frank Richling. Georg Thieme Verlag, 2013. http://dx.doi.org/10.1055/b-0034-82838.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Chevrel, Guillaume, and Virginie Dessus. "voriconazole." In 300 médicaments injectables. Elsevier, 2009. http://dx.doi.org/10.1016/b978-2-294-70698-1.50167-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

"Voriconazole." In Meyler's Side Effects of Drugs. Elsevier, 2016. http://dx.doi.org/10.1016/b978-0-444-53717-1.01643-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

"Voriconazole." In Pediatric Injectable Drugs. American Society of Health-System Pharmacists, 2018. http://dx.doi.org/10.37573/9781585285402.245.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

"Voriconazole." In Extended Stability for Parenteral Drugs. American Society of Health-System Pharmacists, 2017. http://dx.doi.org/10.37573/9781585285280.164.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

"Voriconazole." In Hale’s Medications & Mothers’ Milk™ 2019. Springer Publishing Company, 2018. http://dx.doi.org/10.1891/9780826150356.1078.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

"Voriconazole." In Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions. Elsevier, 2006. http://dx.doi.org/10.1016/b0-44-451005-2/00529-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Voriconazol"

1

Marques, Randu Moreira, Isabelle Eutalia Rodrigues Da Silva, Jamilly Marques De Lino, and Alcione De Oliveira Dos Santos. "CANDIDÍASE NEONATAL, TRATAMENTO E PERSPECTIVAS NO BRASIL: UMA ANÁLISE BIBLIOGRÁFICA." In I Congresso Brasileiro de Doenças Infectocontagiosas On-line. Revista Multidisciplinar em Saúde, 2021. http://dx.doi.org/10.51161/rems/2216.

Full text
Abstract:
Introdução: A candidíase é uma doença causada pelo fungo Candida, sendo no Brasil epidemiologicamente mais frequentes as espécies C. albicans e C. parapsilosis; de caráter oportunista, esse fungo acomete, principalmente: boca, unhas, pele, vagina e esôfago. Em neonatos, os tipos predominantes são candidíase cutânea - relacionada com áreas mais úmidas do corpo do recém-nascido: região púbica e glútea – e oral. A infecção está associada a alterações do sistema imunológico, possibilitando a colonização fúngica no recém-nascido, tornando necessário acompanhamentos mais incisivos e terapêutica hosp
APA, Harvard, Vancouver, ISO, and other styles
2

Ruiz Boy, S., N. Socoro-Yuste, C. Bastida, and D. Soy-Muner. "4CPS-057 Therapeutic drug monitoring of voriconazole." In 25th EAHP Congress, 25th–27th March 2020, Gothenburg, Sweden. British Medical Journal Publishing Group, 2020. http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.158.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hilberg, Ole, Elisabeth Bendstrup, Jann Mortensen, and Charlotte Andersen. "Inhaled Voriconazole - An Efficient Treatment Against Invasive Aspergillosis." In American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a6088.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Pirrone, A., FN Beretta, L. Gambitta, and V. Marini. "5PSQ-045 Cost-effectiveness analysis of isavuconazole versus voriconazole." In Abstract Book, 23rd EAHP Congress, 21st–23rd March 2018, Gothenburg, Sweden. British Medical Journal Publishing Group, 2018. http://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.399.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Gutiérrez Palomo, S., IM Moreno Escudero, A. Rochina Astorga, A. Quesada Asencio, L. Peral Ballester, and A. Navarro Ruiz. "3PC-033 Intracameral and intrastromal voriconazole administration in fusarium keratitis." In 25th EAHP Congress, 25th–27th March 2020, Gothenburg, Sweden. British Medical Journal Publishing Group, 2020. http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.80.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Nishihara, F., T. Hirama, S. Maesaki, et al. "Treatment of Chronic Pulmonary Aspergillosis by Voriconazole Compared with Micafungin." In American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a5936.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Taberner Bonastre, P., A. Aragones Eroles, M. Martinez Sogues, et al. "4CPS-112 Voriconazole therapeutic drug monitoring: relationship with liver toxicity." In 26th EAHP Congress, Hospital pharmacists – changing roles in a changing world, 23–25 March 2022. British Medical Journal Publishing Group, 2022. http://dx.doi.org/10.1136/ejhpharm-2022-eahp.140.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Idoate, AI, L. Leache, and A. Aldaz. "4CPS-058 Avoid simultaneus prescription between linezolid and voriconazole: pharmacokinetic study." In 24th EAHP Congress, 27th–29th March 2019, Barcelona, Spain. British Medical Journal Publishing Group, 2019. http://dx.doi.org/10.1136/ejhpharm-2019-eahpconf.207.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Cadranel, J., B. Philippe, C. Hennequin, et al. "Phase II Trial of Voriconazole (VORI) for Proven Chronic Pulmonary Aspergillosis." In American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a5938.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Mohan, Anant, Pawan Tiwari, Rosemary Poulose, et al. "Intrabronchial voriconazole instillation provides effective hemoptysis control in inoperable pulmonary aspergilloma." In ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.pa2644.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Voriconazol' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography